文献速递神经肿瘤

胶质母细胞瘤预后相关的亚型特异性信号通路与基因组畸变

Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
PubMed 文献 · Neuro Oncol · 2019-01-01

基于癌症基因组图谱数据,通过全基因组Cox回归与基因集富集分析识别胶质母细胞瘤亚型特异性预后核心基因,并在包含608例胶质母细胞瘤的8个公共数据集中验证,同时分析预后相关的染色体畸变与突变。这些亚型特异性改变有望成为新的预后生物标志物和治疗靶点,但拷贝数改变和突变结果因事件数少需进一步验证。

要点

  • 经典型和间质型中MET、IGF1R及PI3K/Akt/mTOR、NF-kB通路基因常为预后核心基因。
  • 经典型特异性预后基因涉及细胞周期、DNA修复和JAK-STAT通路。
  • 间质型特异性预后基因涉及间质细胞运动、PI3K/Akt、MAPK/ERK、Wnt/β-catenin和Wnt/Ca2+通路。

核心结论

  • 这些亚型特异性改变有望作为新的预后生物标志物和治疗靶点,并与胶质母细胞瘤亚型的替代标志物联合应用。
  • 但考虑到事件数少,拷贝数改变和突变的结果需进一步验证。

研究设计与样本

  • 使用癌症基因组图谱数据,通过全基因组Cox回归与基因集富集分析相结合的方法识别亚型特异性预后核心基因。
  • 结果在包含608例胶质母细胞瘤的8个公共数据集中验证。
  • 进一步检查了预后相关的染色体畸变和突变。

主要发现

  • 经典型和间质型中,MET和IGF1R两种受体酪氨酸激酶及RTK下游通路如PI3K/Akt/mTOR和NF-kB的基因常被检测为预后核心基因。
  • 经典型特异性预后核心基因包括细胞周期、DNA修复和JAK-STAT通路基因。
  • 免疫相关基因富集于启动子CpG甲基化与表达呈负相关的预后基因中。
  • 间质型特异性预后基因与间质细胞运动、PI3K/Akt、MAPK/ERK、Wnt/β-catenin和Wnt/Ca2+通路相关。
  • 经典型中6p缺失与较差生存相关,TP53突变与较好生存相关;间质型中PIK3R1或PCLO突变患者预后差;G-CIMP亚型中10q缺失、12p获得或14q缺失患者生存差,且10q缺失与CpG甲基化相对较低且预后差的G-CIMP亚类显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 考虑到事件数少,拷贝数改变和突变的结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A high heterogeneity and activation of multiple oncogenic pathways have been implicated in failure of targeted therapies in glioblastoma (GBM). METHODS: Using The Cancer Genome Atlas data, we identified subtype-specific prognostic core genes by a combined approach of genome-wide Cox regression and Gene Set Enrichment Analysis. The results were validated with 8 combined public datasets containing 608 GBMs. We further examined prognostic chromosome aberrations and mutations. RESULTS: In classical and mesenchymal subtypes, 2 receptor tyrosine kinases (RTKs) (MET and IGF1R), and the genes in RTK downstream pathways such as phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and nuclear factor-kappaB (NF-kB), were commonly detected as prognostic core genes. Classical subtype-specific prognostic core genes included those in cell cycle, DNA repair, and the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway. Immune-related genes were enriched in the prognostic genes showing negative promoter cytosine-phosphate-guanine (CpG) methylation/expression correlations. Mesenchymal subtype-specific prognostic genes were those related to mesenchymal cell movement, PI3K/Akt, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), Wnt/β-catenin, and Wnt/Ca2+ pathways. In copy number alterations and mutations, 6p loss and TP53 mutation were associated with poor and good survival, respectively, in the classical subtype. In the mesenchymal subtype, patients with PIK3R1 or PCLO mutations showed poor prognosis. In the glioma CpG island methylator phenotype (G-CIMP) subtype, patients harboring 10q loss, 12p gain, or 14q loss exhibited poor survival. Furthermore, 10q loss was significantly associated with the recently recognized G-CIMP subclass showing relatively low CpG methylation and poor prognosis. CONCLUSION: These subtype-specific alterations have promising potentials as new prognostic biomarkers and therapeutic targets combined with surrogate markers of GBM subtypes. However, considering the small number of events, the results of copy number alterations and mutations require further validations.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Park AK, Kim P, Ballester LY, et al. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro Oncol. 2019. PMID: 30053126. doi:10.1093/neuonc/noy120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。